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BACKGROUND
Congenital malformations can be manifested as combinations of phenotypes that co-
occur more often than expected by chance. In many such cases, it has proved difficult 
to identify a genetic cause. We sought the genetic cause of cardiac, vertebral, and renal 
defects, among others, in unrelated patients.
METHODS
We used genomic sequencing to identify potentially pathogenic gene variants in families 
in which a person had multiple congenital malformations. We tested the function of the 
variant by using assays of in vitro enzyme activity and by quantifying metabolites in 
patient plasma. We engineered mouse models with similar variants using the CRISPR 
(clustered regularly interspaced short palindromic repeats)–Cas9 system.
RESULTS
Variants were identified in two genes that encode enzymes of the kynurenine pathway, 
3-hydroxyanthranilic acid 3,4-dioxygenase (HAAO) and kynureninase (KYNU). Three 
patients carried homozygous variants predicting loss-of-function changes in the HAAO 
or KYNU proteins (HAAO p.D162*, HAAO p.W186*, or KYNU p.V57Efs*21). Another 
patient carried heterozygous KYNU variants (p.Y156* and p.F349Kfs*4). The mutant 
enzymes had greatly reduced activity in vitro. Nicotinamide adenine dinucleotide (NAD) 
is synthesized de novo from tryptophan through the kynurenine pathway. The patients 
had reduced levels of circulating NAD. Defects similar to those in the patients developed 
in the embryos of Haao-null or Kynu-null mice owing to NAD deficiency. In null mice, 
the prevention of NAD deficiency during gestation averted defects.
CONCLUSIONS
Disruption of NAD synthesis caused a deficiency of NAD and congenital malformations 
in humans and mice. Niacin supplementation during gestation prevented the malforma-
tions in mice. (Funded by the National Health and Medical Research Council of Austra-
lia and others.)
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NAD Deficiency and Congenital Malformations
Major congenital malformations occur in at least 2% of human births.1 There are relatively few identified causes. 
The origins of most malformations have been 
difficult to determine and probably involve ge-
netic and environmental factors or gene–environ-
ment interaction. Although malformations fre-
quently occur in isolation, they also occur in 
combination.2 Vertebral defects, anal atresia, car-
diac defects, tracheoesophageal fistula, renal 
anomalies, and limb abnormalities (VACTERL) 
together represent a nonrandom combination of 
congenital defects without a known cause.3 Per-
sons are considered to have the VACTERL asso-
ciation if they have any three of the above defects 
in the absence of a genetic cause. Our under-
standing of the genetic basis of congenital mal-
formations is increasing, and many causes of iso-
lated organ defects have been identified. Isolated 
heart defects are many and varied and are 
caused by pathogenic variation in approximately 
60 genes.4 Vertebral defects also show variability 
and are caused by mutations in genes associated 
with Notch signal transduction and somitogene-
sis.5-11 However, the genetic causes of isolated car-
diac or vertebral defects appear to have little rele-
vance when these defects occur in combination.12
To identify the genetic basis of multiple con-
genital malformations in individuals, we used 
genomic sequencing to identify potential disease-
causing mutations. We functionally assessed 
these mutations in vitro and defined their role 
in mouse embryogenesis.
Me thods
Study Participants
Patients with congenital vertebral and heart mal-
formations from Families A, B, and C were 
identified by clinical geneticists at the Children’s 
Hospital at Westmead and Liverpool Hospital 
(Australia). Family D underwent diagnostic se-
quencing at GeneDx (United States) and was 
subsequently identified through GeneMatcher13 
(Fig. 1). Patients A, B, and C were part of a series 
of 13 families (3 consanguineous) with multiple 
congenital malformations, including vertebral 
and heart defects. Persons from all 13 families 
underwent sequencing.
Genomic and Genetic Analyses
All the families underwent whole-exome se-
quencing except for Family B, which underwent 
whole-genome sequencing. Methods of library 
Figure 1. Pedigrees of Families with Congenital Malformations and HAAO or KYNU Variants.
Squares indicate male persons, circles female persons, triangles first‑trimester deaths, solid symbols affected per‑
sons (patients), slashes deceased persons, and double horizontal lines consanguineous marriages. All persons in 
Families A, C, and D were evaluated by means of exome sequencing. All persons in Family B were evaluated by means 
of genome sequencing. In family D, two distinct variants in the KYNU gene were identified. Mutated alleles are de‑
picted as “a” or “b” for HAAO and as “c,” “d,” or “e” for KYNU. The reference allele is depicted by a plus sign.
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preparation, sequencing, variant detection, and 
resequencing are described in the Supplemen-
tary Appendix (available with the full text of this 
article at NEJM.org). Details of the enzyme as-
says, the quantification of metabolites in the 
kynurenine pathway, the generation of null al-
leles in mice, and analysis of mice embryos are 
also available in the Supplementary Appendix.
R esult s
Clinical Features of Affected Families
The clinical features of the study participants are 
summarized in Table 1; details are provided in 
the Results section and Table S1 in the Supple-
mentary Appendix. The four families include 
one consanguineous family from Iraq (Family 
A), two consanguineous families from Lebanon 
(Families B and C), and a family from the United 
States without a history of consanguinity (Fam-
ily D) (Fig. 1). There is no other history of con-
genital anomalies or intellectual disability in these 
families. The mother in Family B had insulin-
requiring gestational diabetes. The mother in 
Family C had prepregnancy insulin-requiring 
diabetes, hypercholesterolemia, and a body-mass 
index (BMI, the weight in kilograms divided by 
the square of the height in meters) of 32.8. The 
mother in Family D had a BMI of 29.3. Patient A 
and Patient B were each one of dizygotic twins.
All the affected persons were born with ver-
tebral defects predominantly affecting the thora-
columbar spine. Patients A and B had a spinal 
lipoma, which was associated with sacral agene-
sis in Patient A and with spinal dysraphism in 
Patient B. All the patients had cardiac defects: 
patent ductus arteriosus in Patient C, an atrial 
septal defect in Patient A, and hypoplastic left 
heart in Patients B and D. Patients A, B, and C 
had hypoplastic kidneys, and Patient D had a 
solitary left kidney with moderate chronic kid-
ney disease. Patient C had rhizomelia, and Pa-
tient D had shortened long bones. Patients A 
and C had talipes. Patients A and B had senso-
rineural hearing loss. Patient A had a submu-
cous cleft palate, a bifid uvula, and a laryngeal 
web with persistent laryngeal tracheomalacia. 
Patient B had palsy in the left vocal cord that was 
possibly iatrogenic. None of the patients had a 
tracheoesophageal defect. Patient C had an ante-
rior anus. Patient C died at 4 months of age from 
restrictive respiratory disease due to spondylocos-
tal defects and Patient B at 11 months of age 
from complications of hypoplastic left heart.
In addition to congenital malformations, post-
natal growth and cognitive defects were evident. 
Patients A, B, and C had microcephaly. Patients A 
and D have extreme short stature. Patient A has 
moderate intellectual disability and behavioral 
issues at 12 years of age, and Patient D has 
speech delay at 3 years of age.
Pathogenic Variants in HAAO and KYNU
In the consanguineous families, variants were 
filtered according to a recessive inheritance 
model and a compound heterozygous inheritance 
model and on the assumption that a de novo 
mutation in the patient was a possibility. Addi-
tional filtering was used to select variants that 
were nonsynonymous, rare, and predicted to be 
damaging, and these variants were assessed for 
further evidence of disease causation (Tables S2 
through S7 in the Supplementary Appendix). Of 
these, predicted loss-of-function variants in two 
genes (HAAO, encoding 3-hydroxyanthranilic acid 
3,4-dioxygenase, and KYNU, encoding kynureni-
nase) were identified in three consanguineous 
families and were prioritized for further analy-
sis. HAAO and KYNU are enzymes of the kyn-
urenine pathway and are involved in the synthe-
sis of nicotinamide adenine dinucleotide (NAD) 
(Fig. 2). Pathogenic variants in genes that are 
associated with NAD synthesis were not identi-
fied in the remaining 10 families. Neither HAAO 
nor KYNU has been associated with congenital 
malformation; however, a KYNU missense muta-
tion (p.T198A) has been reported to be associated 
with hydroxykynureninuria (Online Mendelian 
Inheritance in Man [OMIM] number, 236800).14
Sanger sequencing confirmed variant segre-
gation with disease (Fig. 1, and Fig. S2 in the 
Supplementary Appendix). In Family A, the pa-
tient was homozygous for a c.483dupT variant in 
HAAO (ClinVar accession number, SCV000540919), 
leading to a stop codon (p.D162*). In Family B, 
the patient was homozygous for a c.558G→A 
variant in HAAO (ClinVar accession number, 
SCV000540920), leading to a stop codon (p.W186*). 
In Family C, the patient was homozygous for a 
c.170-1G→T splicing variant in KYNU (ClinVar 
accession number, SCV000540921), leading to a 
stop codon downstream (p.V57Efs*21). In all 
three families, the unaffected parents and sib-
lings were either heterozygous for the mutation 
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or homozygous for the reference allele, indicat-
ing a recessive inheritance pattern. In Family D, 
the patient was compound heterozygous for KYNU 
variants c.468T→A (ClinVar accession number, 
SCV000540922) and c.1045_1051delTTTAAGC 
(ClinVar accession number, SCV000540923), which 
were inherited from the father and mother, re-
spectively; each variant results in a stop codon 
(p.Y156* and p.F349Kfs*4, respectively). The loca-
tions of the variants in HAAO and KYNU and 
their corresponding protein variants are shown 
in Figure S3 in the Supplementary Appendix.
In Vitro Activity of Mutant HAAO and KYNU
We tested the activity of the truncated enzymes. 
For HAAO, we quantified the conversion of 3-hy-
droxyanthranilic acid (3HAA) to 2-amino-3-car-
boxymuconate-6-semialdehyde (ACMS). For KYNU, 
we quantified the conversion of 3-hydroxykyn-
urenine (3HK) to 3HAA. (The enzyme assays are 
described in the Supplementary Appendix.) We 
tested the identified HAAO and KYNU variant 
proteins as well as KYNU p.T198A, which is as-
sociated with hydroxykynureninuria but not con-
genital malformation.14 The specific activity of 
all the truncated HAAO and KYNU enzymes was 
0 to 19% as high as the activity of nonmutant 
enzymes (Fig. S4 and Table S8 in the Supple-
mentary Appendix). By contrast, the activity of 
KYNU p.T198A was 64% as high as the activity 
of the nonmutant enzyme.
Levels of Metabolites in the Kynurenine 
Pathway and NAD Levels
We predicted that loss of HAAO or KYNU activ-
ity would lead to increased plasma levels of 
metabolites upstream of these enzymes and re-
duced levels downstream. Patients A and B (homo-
zygous HAAO stop codon) had upstream 3HAA 
levels that were 64 and 385 times the levels in 
unaffected heterozygous family members, respec-
tively. Downstream of HAAO, levels of NAD+ 
(the oxidized form of NAD) and of NAD(H) (the 
sum of NAD+ and NADH, the reduced form of 
NAD) were one third to one quarter of the levels 
in unaffected heterozygous family members 
(Tables 1 and 2, and Table S9 in the Supplemen-
tary Appendix). Plasma was not available from 
Family C. Patient D (compound heterozygous for 
KYNU truncating mutations) had an upstream 
3HK level that was 161 times the level in unaf-
fected family members and a downstream NAD(H) T
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level that was one seventh of the level in unaf-
fected family members.
Modeling of Disease in Mice Null for Haao  
or Kynu
We generated mice with a null allele for Haao or 
Kynu (Fig. S5 in the Supplementary Appendix). 
Enzyme assays confirmed that the edited alleles 
were null (Fig. S6 in the Supplementary Appen-
dix). Intercrosses of mice that were heterozygous 
null for Haao or for Kynu produced embryos in 
the expected mendelian ratio of genotypes. Un-
expectedly, all the embryos were normal (Tables 
S10 and S11 in the Supplementary Appendix). 
We next quantified metabolites upstream and 
downstream of Haao and of Kynu in adult 
mouse serum. Haao−/− mice had 3HAA levels that 
were more than 100 times the levels in Haao+/− 
mice and wild-type mice (Table S12 in the Sup-
plementary Appendix). Similarly, Kynu−/− mice had 
3HK levels that were more than 70 times the 
levels in Kynu+/− mice and wild-type mice, a 
metabolic finding consistent with our findings 
in humans (Tables 1 and 2, and Table S9 in the 
Supplementary Appendix). By contrast, NAD(H) 
levels were similar in all the mice, regardless of 
genotype (Table S12 in the Supplementary Ap-
pendix). This suggested that elevated levels of 
metabolites upstream of HAAO or KYNU in 
humans did not cause congenital malformation 
and underscored a deficit in the NAD level as the 
cause.
NAD is produced by two pathways: one re-
quires dietary tryptophan, and the other requires 
dietary niacin (Fig. 2). The NAD de novo synthe-
sis pathway catabolizes tryptophan through the 
kynurenine pathway, and the NAD salvage path-
way converts niacin and other precursors into 
NAD (independent of KYNU and HAAO). The 
niacin status of mice as measured by the con-
centration of NAD in whole blood is at least four 
times that in humans, possibly because mice 
convert tryptophan to NAD more efficiently,15 
and they consume more tryptophan or niacin 
per unit of body weight owing to a higher basal 
metabolic rate.16 In mice, reduced niacin status 
occurs only when both de novo synthesis of NAD 
is blocked and niacin is removed from the diet.17
During development, embryos receive niacin 
from the mother and generate their own. It is 
therefore possible that maternal niacin has a 
buffering effect and protects the null mouse 
embryos from the development of NAD defi-
ciency. We therefore sought to reduce niacin levels 
in pregnant mice that were heterozygous for a 
null allele (Haao+/− or Kynu+/−). As a first attempt 
to mimic the reduced NAD levels in humans, 
these mice were fed a niacin-free diet during 
pregnancy. In litters from Haao+/− or Kynu+/− inter-
crosses, embryos had the expected mendelian 
ratio of genotypes and were phenotypically nor-
mal (Tables S11 and S13 in the Supplementary 
Appendix). This observation suggested that het-
Figure 2. Synthesis of Nicotinamide Adenine Dinucleotide 
(NAD).
NAD is synthesized de novo from the essential amino 
acid L‑tryptophan and salvaged from nicotinamide. 
Tryptophan and niacin (vitamin B3), which is supplied 
as nicotinic acid and nicotinamide, represent dietary in‑
puts. Details on NAD synthesis are provided in Figure S1 
in the Supplementary Appendix.
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L-tryptophan (diet)
N-Formylkynurenine
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3-Hydroxykynurenine (3HK)
3-Hydroxyanthranilic acid (3HAA)
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6-semialdehyde (ACMS)
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erozygous null female mice (i.e., those with one 
normal and one null allele of Haao or of Kynu) 
that receive a niacin-free diet produce sufficient 
NAD from dietary tryptophan to sustain normal 
embryonic development.
To preclude maternal NAD production from 
the de novo synthesis pathway in addition to the 
salvage pathway, null female mice (Haao−/− or 
Kynu−/−) were mated with Haao+/− or Kynu+/− male 
mice and fed a niacin-free diet. All the embryos 
died, regardless of genotype (Tables S11 and S14 
in the Supplementary Appendix). Death also oc-
curred when the niacin-free diet was limited 
from embryonic day 0.5 to embryonic day 4.5, 
5.5, or 6.5 (Tables S11 and S14 in the Supple-
mentary Appendix). We determined that a niacin-
free diet supplemented with 5 mg of nicotinic 
acid per liter of drinking water between embry-
onic day 7.5 and embryonic day 12.5 better sus-
tained embryogenesis in null mothers. Despite 
a large number of resorptions, live null embryos 
were present (Tables S11 and S15 in the Supple-
mentary Appendix). All the Haao+/− and Kynu+/− 
embryos were normal. By contrast, all the 
Haao−/− and Kynu−/− embryos had multiple de-
fects, including defects in vertebral segmenta-
tion, heart defects, small kidney, cleft palate, 
talipes, syndactyly, and caudal agenesis (Fig. S7 
and Tables S15 and S16 in the Supplementary 
Appendix). NAD levels in null mouse embryos 
were one half the levels in unaffected heterozy-
gous littermates at embryonic day 9.5 (Fig. 3). 
This observation indicates that in both mice and 
humans, loss of embryonic NAD leads to em-
bryo defects and death. It is the embryonic NAD 
deficit that causes defects rather than the mater-
nal deficit, because null mothers produce normal 
heterozygous embryos (Table S15 and Fig. S7 in 
the Supplementary Appendix).
To prove that NAD deficiency was disrupting 
embryogenesis, pregnant null mice were fed a 
niacin-free diet as before, and water was supple-
mented with 10 or 15 mg of nicotinic acid per 
liter. Because mice consume 1.3 liters of water 
per kilogram of food,18 we calculated that with 
this regimen mice would consume 14% of the 
niacin equivalent in complete mouse chow (90 mg 
per kilogram). Litters from these mice contained 
embryos with genotypes in the expected mende-
lian ratio. With 10 mg of nicotinic acid per liter, 
null embryos were normal except for kidneys 
that were 30% smaller than those in heterozy-
gous controls; with 15 mg of nicotinic acid per 
liter, all the embryos were normal (Table S15 in 
the Supplementary Appendix). We also observed 
a dose-dependent increase in embryonic NAD(H) 
levels in response to maternal niacin supplemen-
tation (Fig. 3), a finding consistent with the ab-
Variable Family B
Mean in Unaffected 
Family Members
Level in Patient 
versus Mean
I.1 I.2 II.1 II.2 II.3 II.4
Upstream of HAAO
Tryptophan (μM) 52.6 39.5 62.0 48.9 85.3 63.6 57.7 1.1 times the mean
Kynurenine (μM) 1.2 1.1 1.1 1.6 1.6 1.6 1.3 1.2 times the mean
3HK (nM) 4.1 41.3 4.1 15.6 79.4 98.4 28.9 3.4 times the mean
3HAA (nM) 114.8 84.3 55.2 65.4 171.5 37,819.8 98.3 384.9 times the mean
Downstream of HAAO
Picolinic acid (nM) 32.0 NA 31.7 26.4 35.5 33.7 31.4 1.1 times the mean
Quinolinic acid (nM) 113.5 NA 133.6 168.4 217.3 40.2 158.2 1/4th of the mean
NAD+ (nM) 24.4 25.4 22.3 21.5 27.7 3.6 24.3 1/7th of the mean
NADH (nM) 17.3 16.0 19.7 16.3 18.4 8.1 17.5 1/2 of the mean
NAD(H) (nM) 41.7 41.4 42.0 37.8 46.0 11.7 41.8 1/4th of the mean
*  Data on Families A and D are provided in Table S9 in the Supplementary Appendix. Plasma was not available from Family C.
Table 2. Alteration in Levels of Metabolites in the Kynurenine Pathway and in NAD Levels in Plasma from Patient B (Family Member II.4).*
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sence of a phenotype. These data show that 
embryo death and defects were specifically due 
to a deficit of NAD in embryos and that niacin 
supplementation prevented the disruption of 
embryogenesis.
Discussion
We identified mutations blocking de novo NAD 
synthesis that cause multiple congenital malfor-
mations, including those found in the VACTERL 
association. The NAD de novo synthesis pathway 
catabolizes tryptophan, leading to the production 
of NAD. Although metabolite levels upstream of 
the block are elevated and the metabolites have 
postnatal functions,19 we found that it is the 
deficiency in embryonic NAD, downstream of 
the block, that is disrupting embryogenesis. We 
found that in mice, supplementing dietary nia-
cin during gestation prevents embryo defects 
caused by NAD deficiency. We evaluated the 
pathogenicity of the HAAO and KYNU variants 
according to American College of Medical Ge-
netics and Genomics guidelines.20 On the basis 
of the predicted deleterious effects that were 
confirmed by in vitro enzyme assays, an absence 
or extremely low frequency of minor alleles, and 
the recessive inheritance pattern, we conclude 
that all the HAAO and KYNU variants that were 
identified in this study are pathogenic (Table S17 
in the Supplementary Appendix).
NAD deficiency is linked to disease through 
genetic and environmental means. Severe niacin 
deficiency causes pellagra, characterized by der-
matitis, diarrhea, dementia, and death.21 Although 
pellagra is rare today, niacin deficiency that is 
caused by dietary inadequacies, malabsorption of 
nutrients, and drug interference is still observed.21 
Moreover, niacin deficiency is common during 
pregnancy.22 Niacin deficiency can also be inher-
ited. Hartnup disease, characterized by dermatitis 
and neurologic and behavioral defects, is caused 
by mutation of SLC6A19, which is required for 
the transport of neutral amino acids, including 
tryptophan.23 NAD synthesis is also reduced by 
pathophysiological factors such as type 2 diabetes, 
obesity, and inflammation.22,24-26 These may have 
been confounding factors in Families B, C, and D.
Our findings increase understanding of the 
genetic and environmental causes of congenital 
malformation. Our discovery that the genetic 
disruption of NAD synthesis causes congenital 
malformations suggests that mutation of many 
genes might have the same effect (Fig. S1 in the 
Supplementary Appendix). These include genes 
required for de novo synthesis of NAD, such as 
genes encoding tryptophan transporters (SLC7A5, 
SLC7A8, and SLC6A19), genes encoding enzymes 
of the kynurenine pathway (TDO2, IDO1-2, AFMID, 
KMO, KYNU, and HAAO), and genes encoding 
enzymes that convert quinolinic acid to NAD 
Figure 3. Effect of Niacin Supplementation on Levels of NAD in Null Mouse 
Embryos.
Female mice that were homozygous null for Haao or Kynu were mated with 
heterozygous male mice. Pregnant mice were fed a niacin‑free diet supple‑
mented with 5, 10, or 15 mg of nicotinic acid per liter of drinking water from 
embryonic day 7.5 to 9.5. Embryos were harvested at embryonic day 9.5, 
and levels of NAD(H) (the sum of NAD+ and NADH) were quantified. The 
difference between groups was tested with the use of a one‑way analysis‑
of‑variance test based on log2‑transformed data, followed by Dunnett’s 
multiple‑comparison test (all other groups vs. null mice receiving 5 mg of 
nicotinic acid per liter). The middle lines of the I bars indicate mean values, 
and the I bars ±1 SD.
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(QPRT, NMNAT1-3, and NADSYN1). Furthermore, 
genes encoding enzymes of the NAD salvage 
pathway (NAMPT and NMNAT1-3) and genes re-
quired for the transport of nicotinic acid (SLC5A8 
and SLC22A13) or the uptake of dietary niacin 
(nicotinic acid, nicotinamide, or nicotinamide 
riboside) or its entry into NAD-producing path-
ways (NAPRT, PNP, and NMRK1,2) could also be 
candidates for causing congenital malformations. 
It is noteworthy that mutation of NMNAT1 causes 
the retinal degenerative condition Leber’s con-
genital amaurosis type 9 (OMIM number, 608553). 
Here, the almost-normal enzymatic activity of 
mutant proteins would preclude a broad pheno-
type such as congenital malformation.27
NAD is a cofactor with broad cellular effects 
that is involved in ATP production, macromolecu-
lar synthesis, PARP-dependent DNA repair, and 
sirtuin-dependent protein deacetylation.28 NAD+ 
or NADH participates in approximately 400 re-
dox reactions, NADP+ or NADPH participates in 
approximately 30 redox reactions, and NAD+ is 
consumed in approximately 50 reactions in-
volving PARP-dependent DNA repair or sirtuin-
dependent deacetylation.28 Given the various roles 
of NAD, there are many possible ways by which 
a deficit of it might disrupt embryogenesis.
First, NAD is central to energy metabolism, 
serving as an essential coenzyme in glycolysis, 
the tricarboxylic acid cycle, and the mitochon-
drial electron transport chain, and is also central 
to the production of macromolecules, including 
nucleotides. Embryogenesis is characterized by 
dynamic, well-orchestrated cellular proliferation 
and differentiation. NAD deficiency is therefore 
likely to most affect tissues undergoing the great-
est change.
Second, NAD levels regulate sirtuin-mediated 
deacetylation, which modulates transcription fac-
tors and metabolic enzymes that promote mito-
chondrial oxidative function and enhance cell 
survival under stress conditions.29-31 Sirtuin ac-
tivity is required during embryogenesis and af-
fects the fate of stem cells and progenitor cells; 
loss of activity causes multiple organ defects.32
Third, DNA repair is active during rodent 
embryogenesis and is required for normal devel-
opment.33 There is evidence that NAD deficiency 
impairs DNA repair28 and that a DNA fragmenta-
tion disorder in humans, Fanconi’s anemia, can 
result in multiple congenital malformations de-
fining the VACTERL association.3
In the patients we describe here, there was 
consistency in the tissues affected but variability 
in phenotype. Given the phenotypic spectrum and 
the essential role of NAD, it is possible that ad-
ditional variable phenotypes may yet be discov-
ered. Such variability is probably due to a range 
of factors, including gene modifiers in both the 
mother and the affected child; maternal physiol-
ogy that is influenced, for example, by diabetes; 
diet, including the intake of niacin and trypto-
phan; and other factors affecting NAD produc-
tion, salvage, and consumption. We theorize that 
supplementation with high-dose niacin (140 mg 
per day, which is 10 times the U.S. recommended 
daily allowance for women) before and during 
pregnancy might prevent recurrence of disease in 
these four families. It is also possible that niacin 
supplementation may benefit the speech and 
developmental delays in the surviving patients.
In conclusion, many genetic and environmen-
tal factors have the potential to cause NAD defi-
ciency during gestation. We propose that cases 
of congenital malformation that occur because 
of a deficit in NAD be collectively referred to as 
congenital NAD deficiency disorders.
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